Genprex announced a collaboration with Roche Diagnostics to validate TROP2 and PTEN biomarkers to refine patient selection for NSCLC clinical trials.
Key Highlights:
- Collaboration with Roche Diagnostics to validate TROP2 assay for patient selection in non‑small cell lung cancer trials.
- Genprex data: high TROP2 H‑scores (>100) and low PTEN H‑scores (<100) correlated with longer PFS in prior studies.
- Roche received FDA Breakthrough Device Designation for an AI‑driven companion diagnostic using a TROP2 score; Genprex will use the same TROP2 antibody.
- Validation studies expected to be completed approximately by end of 2026, with integration into Genprex’s NSCLC program thereafter, subject to results.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.